There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Intellia Therapeutics Inc. (NTLA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $1.02, or 2.54%, to $41.10. The Intellia Therapeutics Inc. has recorded 95,296 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE).
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
As a NASDAQ listed company, NTLA falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $40.08 and fluctuated between $43.61 as its day high and $39.97 as its day low. The current market capitalization of Intellia Therapeutics Inc. is $3.58B. A total of 1.03 million shares were traded on the day, compared to an average of 1.23M shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, NTLA has seen 4 BUY and 10 SELL insider trades, representing the acquisition of 17,597 and the disposition of 21,385 shares. Over the last 12 months, there were 13 BUYs and 11 SELLs from insiders. Insiders purchased 63,944 shares during that period but sold 21,490.
In the most recent transaction, Sepp-Lorenzino Laura sold 2,330 shares of NTLA for 38.48 per share on Jan 05. After the transaction, the EVP, Chief Scientific Officer now owns 17,629 company shares. In a previous transaction on Jan 04, LEONARD JOHN M sold 6,673 shares at 37.21 per share. NTLA shares that President and CEO owns now total 766,825.
Among the insiders who sold shares, Lebwohl David disposed of 2,574 shares on Jan 04 at a per-share price of $37.21. This resulted in the EVP, Chief Medical Officer holding 25,687 shares of NTLA after the transaction. In another insider transaction, Sepp-Lorenzino Laura sold 2,508 shares at $37.21 per share on Jan 04. Company shares held by the EVP, Chief Scientific Officer now total 19,959.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for NTLA in the last 3 months, the mean price target is $96.32 with high estimates of $168.00 and low estimates of $39.00. In terms of 52-week highs and lows, NTLA has a high of $78.58 and a low of $32.44.
As of this writing, NTLA has an earnings estimate of -$1.39 per share for the current quarter. EPS was calculated based on a consensus of 25 estimates, with a high estimate of -$0.83 per share and a lower estimate of -$1.7. The company reported an EPS of -$1.33 in the last quarter, which was -1.50% lower than expectations of -$1.31.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 28 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NTLA is Sell with a score of 4.61. A total of 21 analysts rated the stock as Buy while 2 rated it as Overweight while 5 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.